Inventiva (IVA) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
IVA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.67 |
| 52 Week High | €7.98 |
| 52 Week Low | €2.85 |
| Beta | 0.95 |
| 1 Month Change | -7.50% |
| 3 Month Change | 24.89% |
| 1 Year Change | 82.90% |
| 3 Year Change | 71.82% |
| 5 Year Change | -60.49% |
| Change since IPO | -57.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.5% | 3.6% | 4.4% |
| 1Y | 82.9% | 41.4% | 31.9% |
Return vs Industry: IVA exceeded the US Biotechs industry which returned 40.3% over the past year.
Return vs Market: IVA exceeded the US Market which returned 31% over the past year.
Price Volatility
| IVA volatility | |
|---|---|
| IVA Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IVA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IVA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 84 | Andrew Obenshain | inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.
Inventiva S.A. Fundamentals Summary
| IVA fundamental statistics | |
|---|---|
| Market cap | US$1.04b |
| Earnings (TTM) | -US$408.79m |
| Revenue (TTM) | US$9.15m |
Is IVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVA income statement (TTM) | |
|---|---|
| Revenue | €7.93m |
| Cost of Revenue | €0 |
| Gross Profit | €7.93m |
| Other Expenses | €362.06m |
| Earnings | -€354.14m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 25, 2026
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,468.05% |
| Debt/Equity Ratio | -1,445.4% |
How did IVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/06 14:10 |
| End of Day Share Price | 2026/04/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inventiva S.A. is covered by 23 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Edward Nash | Canaccord Genuity |
| Etzer Darout | Guggenheim Securities, LLC |